Abstracts tagged "serologic tests and systemic lupus erythematosus (SLE)"

Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Juan Gabriel Ovalles-Bonilla^1,2, Francisco Javier López Longo³, Iñigo Rúa-Figueroa⁴, María Galindo⁵, Jaime Calvo-Alén⁶, Juan Carlos Nieto², Julia Martínez-Barrio³, Roberto González⁷, Belen Serrano⁸, Iustina Janta², Carlos M Gonzalez⁹, Indalecio Monteagudo² and JM Pego-Reigosa¹⁰, ¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ⁷Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁹Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…
Abstract Number: 2915 • 2015 ACR/ARHP Annual Meeting
The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort
Kristy Yap¹, Murray Urowitz^1,2, Quenby Mahood³, Jorge Medina-Rosas⁴, Arthy Sabapathy⁵, Daeria Lawson⁴, Jiandong Su¹, Dafna Gladman¹ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Library Services, Institute of Work and Health, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To study the utility of lupus serology as a predictor for kidney graft outcome in: a) a systematic review (SR) of the literature and…
Abstract Number: 1578 • 2013 ACR/ARHP Annual Meeting
Decreased Sensitivity Of a Commercial Anti-dsDNA Assay In Patients With Moderately To Severely Active Systemic Lupus Erythematosus
Munther A. Khamashta¹, Gabor G. Illei², Stephen Yoo², Liangwei Wang³ and Warren Greth², ¹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²Clinical Development, MedImmune, LLC, Gaithersburg, MD, ³Biostatistics, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anti-dsDNA autoantibodies are highly specific for SLE. Anti-dsDNA positivity is an important eligibility criterion in many SLE studies, and decreases in anti-dsDNA levels are…
Abstract Number: 585 • 2013 ACR/ARHP Annual Meeting
Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Christine Peschken⁶, William Foulkes¹, Yvan St. Pierre⁷, Patrice Chrétien Raymer⁷, Basile Tessier Cloutier⁸, Guillermo Ruiz-Irastorza⁹, Ann E. Clarke¹ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁰, ¹McGill University, Montreal, QC, Canada, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁸Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹⁰(coordinating centre), Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting…
Abstract Number: 1392 • 2012 ACR/ARHP Annual Meeting
Clinical Correlation with Anti Double Stranded Deoxyribonucleic Acid Via Enzyme Linked Immunoassay Versus Multiplex Immunoassay
Megan L. Krause¹, Melissa R. Snyder², Cynthia S. Crowson³, Abigail B. Green³ and Kevin G. Moder⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: In systemic lupus erythematosus (SLE), antibodies to double-stranded DNA (dsDNA) are utilized for disease classification and assessment of activity. Enzyme immunoassays (EIAs) and multiplex…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].